

Qrono Named Pittsburgh Tech 50 Awards Finalist

Pittsburgh Technology Council to Name Winners on Oct. 10, 2013

PITTSBURGH Aug 13, 2013 – Qrono Inc., a specialty pharma company focusing on long-acting injectables, today announced that the Pittsburgh Technology Council has named it a Tech 50 Awards Finalist in the Innovator of the Year Category.

The Pittsburgh Technology Council's annual Tech 50 Awards recognize southwestern Pennsylvania's most successful, innovative, and thought-leading technology companies, which have become the backbone of Pittsburgh's new economy.

The awards represent transformative technology centers of excellence with tech companies at all stages of growth. Tech 50 also recognizes the region's top tech executive.

"Each year, the Council canvasses the region for the most distinguished public and private technology-oriented companies, and the Tech 50 awards honor those companies that demonstrated the strongest growth and advancement in product or sales success, financial strength, corporate citizenship, job growth and retention and innovative product or technology," said Audrey Russo, President and CEO, Pittsburgh Technology Council. "We are excited to announce the category winners at the awards gala this fall. It is truly a night to celebrate our region's technology companies and the contributions they have made to our economic vitality."

"It is an honor to be recognized among the top tier of Pittsburgh's most innovative companies, and we are thrilled to be a part of the region's growing community of life science companies," said CEO Larry Zana. "We consider our technology to be a game changer for the pharmaceutical industry, enabling better medicines and better patient outcomes."

Tech 50 winners will be announced on October 10, 2013 at the Wyndham Grand Pittsburgh.

For further information on Qrono please visit www.qrono.com.

For more information on Tech 50, visit <http://tech50.pghtech.org>. For more information on the Pittsburgh Technology Council, visit www.pghtech.org.

About Qrono:

[Qrono Inc.](http://www.qrono.com) is a specialty pharmaceutical company that reformulates approved drugs and creates long-acting injectable medications with improved clinical and economic benefits for patients and other healthcare stakeholders. These long-acting drug formulations enable a single administration of active pharmaceutical ingredient (API) to provide a therapeutic effect ranging from several days to many weeks or months. Qrono collapses the time and cost to develop these formulations and at the same time reducing technical and regulatory risk. Our pipeline strategy focuses on drugs with known safety profiles in therapeutic areas with either high non-adherence or with drug delivery challenges. We further focus on off-patent medications to take advantage of the accelerated 505(j) and 505(b)(2) FDA regulatory pathways.

For further information, please contact: Larry Zana

CEO and Co-Founder
Qrono, Inc.
4551 Forbes Ave., Ste. 301
Pittsburgh, PA 15213
Phone: 412-213-8788
Email: lzana@qrono.com
Internet: <http://www.qrono.com>